Topic 1: Review of Pharmacokinetics, Pharmacodynamics and basics of Drug/Drug and Drug/ Disease Interaction

Topic 2: Polypharmacy in the Elderly

Topic 3: Infectious Disease: Beta Lactam allergy de-listing,New anti-infectives (inpatient and outpatient),HIV pre-exposure prophylaxis (PreP)- Apretude (Long-acting injectable cabxxx), new (Long-acting injectable treatment: CABENUVA (cabxxx with rilxxx)-1hr

Topic 4: A Review of Current Guidelines for the Treatment of Obesity-Drugs.-0.5 hr

Topic 5: Cardiovascular disease: HTN, Lipids, and Heart Failure, AFib and DOACs-2 hrs

Topic 6: Immunomodulators and rheumatology medications for RA and gout, drugs-0.5 hrs

Topic 7: Vitamins and Minerals

Topic 8: Overview of FDA Communications: New Drug Approvals, New Indications, New Warnings

Topic 9: Pharmacotherapy of PTSD, depression, and anxiety, use of Kxxxx in mood disorders (e.g., depression, PTSD) and use of psilocybin (LSD-NONE) in mood disorders (e.g., depression, PTSD) with a discussion of cardiovascular adverse effects with some psychiatric medication

Topic 10: Overview acute care/emergency care including hypertensive emergency, Diabetic ketoacidosis (DKA), acute coronary syndrome, acute stroke, asthma exacerbations / other shortness of breath, and sepsis work-up

Topic 11: Contraception, pregnancy, lactation and abortion

Topic 1: Review of Pharmacokinetics, Pharmacodynamics and basics of Drug/Drug and Drug/ Disease Interaction

1. Identify common drug interaction mechanisms including cytochrome P450 enzymes.
2. Identify relevant clinical drug interactions for common medications.
3. Delineate assessment and management strategies for each drug interaction.

Topic 2: Polypharmacy in the Elderly

1. Recognize factors leading to polypharmacy in the elderly.
2. Define inappropriate medications for elderly patients.
3. Describe tools to screen patients for polypharmacy.
4. Delineate best practices in polypharmacy through patient cases.

Topic 3: Infectious Disease: Beta Lactam allergy de-listing,New anti-infectives (inpatient and outpatient),HIV pre-exposure prophylaxis (PreP)- Apretude (Long-acting injectable cabxxx), new (Long-acting injectable treatment: CABENUVA (cabxxx with rilxxx)-1hr

1. Topic 3: Infectious Disease
2. Topic 3A.: Review and discuss appropriate penicillin allergy assessment and intervention strategies for management.
3. Topic 3B: Discuss and determine overall role of newer antimicrobials.
4. Topic 3C: 1. Review standard and new drugs for prevention of HIV infection (HIV Prep) in High Risk Individuals.

Topic 4: A Review of Current Guidelines for the Treatment of Obesity-Drugs.-0.5 hr

1. Describe appropriate patient populations for weight loss pharmacotherapy.
2. Delineate key characteristics of various pharmacotherapy options including GLP-1 agonists.

Topic 5: Cardiovascular disease: HTN, Lipids, and Heart Failure, AFib and DOACs-2 hrs

1. Review medications and lifestyle modifications that are recommended for the treatment of cardiovascular disease
2. Apply recommendations from the American College of Cardiology/American Heart Association for treatment of patients with hypertension, hypercholesterolemia, heart failure with reduced ejection fraction and atrial fibrillation
3. Examine results from newer cardiovascular outcome trials evaluating the use of medications hypercholesterolemia and heart failure with reduced ejection fraction
4. Define the evidence and role in therapy of non-statin medications in the treatment of hypercholesterolemia
5. Create treatment plans that reduce the risk of cardiovascular disease

Topic 6: Immunomodulators and rheumatology medications for RA and gout, drugs-0.5 hrs

1. Compare and contrast the appropriate use, risks and benefits associated with colchicine, uric acid lowering drugs, steroids and NSAIDs in the management and prevention of gout
2. Explain the roles in therapy and safety concerns for non-biologic disease modifying antirheumatic agents (DMARDs), biologic DMARDs, corticosteroids, and NSAIDs in the treatment of RA

Topic 7: Vitamins and Minerals

1. Review the functions of vitamins and minerals in the body.
2. Match the diseases caused with their vitamin deficiencies.
3. List foods high in certain vitamins and minerals.
4. Examine problems for vitamin and mineral deficiencies.

Topic 8: Overview of FDA Communications: New Drug Approvals, New Indications, New Warnings

1. Identify recent FDA drug communications, including but not limited to, labeling changes, warnings, new indications, new dosage forms and MedWatch alerts.
2. Discuss the new drugs with respect to their pharmacology, pharmacokinetics, approved and unapproved indications.
3. Describe their adverse effects and drug interaction that may affect patient compliance.

Topic 9: Pharmacotherapy of PTSD, depression, and anxiety, use of Kxxxx in mood disorders (e.g., depression, PTSD) and use of psilocybin (LSD-NONE) in mood disorders (e.g., depression, PTSD) with a discussion of cardiovascular adverse effects with some psychiatric medication

1. Discuss traditional agents used to manage depression, anxiety and PTSD
2. Identify the role of newer agents (e.g., ketamine, psilocybin) in the treatment of depression, anxiety, and PTSD
3. Recognize cardiovascular adverse effects of psychiatric medications
4. Discuss the impact of genetics on drug response and its role in the pharmacologic management of patients
5. Explain specific important pharmacokinetic variations with pharmacologic agents in the treatment of mood disorders

Topic 10: Overview acute care/emergency care including hypertensive emergency, Diabetic ketoacidosis (DKA), acute coronary syndrome, acute stroke, asthma exacerbations / other shortness of breath, and sepsis work-up

1. Manage cardiac and thromboembolic related emergencies: hypertensive emergency, acute coronary syndrome, acute stroke, and rapid response scenarios
2. Outline the key tenets of diabetic ketoacidosis (DKA) management
3. Discuss best practices for improving outcomes in acute respiratory failure and sepsis

Topic 11: Contraception, pregnancy, lactation and abortion

1. Describe pharmacologic properties and considerations of various forms of contraception
2. Identify key recommendations and updates for contraception, emergency contraception, and options for medication abortions                        
3. Evaluate the use of various forms of contraception in specific patient cases and scenarios
4. Recognize updates in pregnancy and lactation categories for medications
5. Discuss specific patient considerations related to updated pregnancy and lactation considerations

• University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

• As an ACPE accredited provider, University Learning Systems is able to report credit directly to CPE Monitor. Credit for pharmacists is reported automatically to CPE-Monitor upon completion of the course. NO statement of credit is provided.

• All other professions will receive a statement of credit upon completion of the course.

• ACPE Credit is accepted by nurse practitioner certification organizations for pharmacology and general CE credit.

• University Learning Systems is approved by the California Board of Registered Nursing and is a CE Broker approved provider for pharmacy, nursing and medicine.

• This course provides Category 2 credit for physicians and physician assistants.

• Credit to CE Broker is reported manually at this time. Please provide your state license number if you need credit reported to CE Broker.

• These courses were recorded August 28-29, 2023 and are valid for credit until August 28, 2026.